What is the guideline‑recommended antibiotic regimen for a patient with Acinetobacter baumannii bacteremia associated with an internal jugular vein catheter?

Treatment of Acinetobacter baumannii Bacteremia from Internal Jugular Catheter

For catheter-related A. baumannii bacteremia, immediately obtain susceptibility testing and initiate high-dose ampicillin-sulbactam (9-12 g sulbactam daily as 4-hour infusions) if the isolate is sulbactam-susceptible (MIC ≤4 mg/L), or use colistin-based combination therapy if sulbactam-resistant or carbapenem-resistant. 1, 2

Initial Management Algorithm

Step 1: Remove the Catheter and Obtain Cultures

• Remove the internal jugular catheter immediately, as catheter retention is associated with treatment failure in catheter-related bacteremia 3, 4
• Obtain blood cultures from both the catheter and peripheral sites before initiating antibiotics 2
• Send isolate for susceptibility testing including sulbactam MIC determination using E-test or broth microdilution (automated methods are unreliable) 2

Step 2: Determine Resistance Pattern and Select Therapy

For Carbapenem-Susceptible A. baumannii:

• Use carbapenems (imipenem 0.5-1 g every 6 hours or meropenem 2 g every 8 hours) as first-line therapy in areas with low carbapenem resistance 1, 2
• Do NOT use ertapenem—it lacks activity against A. baumannii despite being a carbapenem 2
• Alternatively, use high-dose ampicillin-sulbactam if sulbactam MIC ≤4 mg/L, which achieves equivalent outcomes with lower nephrotoxicity (15% vs 33% with colistin) 2, 5

For Carbapenem-Resistant A. baumannii (CRAB):

If Sulbactam MIC ≤4 mg/L (Preferred Option):

• Ampicillin-sulbactam: 3 g sulbactam every 8 hours as 4-hour infusions (total 9-12 g sulbactam daily) 1, 2, 6
• This regimen is preferred over polymyxins due to superior safety profile and comparable efficacy 2, 5
• The 4-hour infusion optimizes pharmacokinetics and allows treatment of isolates with MIC up to 8 mg/L 1, 2

If Sulbactam-Resistant or MIC >4 mg/L:

• Colistin (polymyxin E): Loading dose 6-9 million IU, then 4.5 million IU every 12 hours 1
• Polymyxin B: Loading dose 2-2.5 mg/kg, then 1.5-3 mg/kg/day in 2 doses (lower nephrotoxicity than colistin) 1

Step 3: Consider Combination Therapy for Severe Infection

Indications for combination therapy (two active agents): 2

• Septic shock at presentation
• Severe sepsis with predicted mortality >25%
• Clinical failure on monotherapy
• Sulbactam MIC at upper limit of susceptibility (MIC = 4 mg/L)

Recommended combinations: 2

• Colistin + sulbactam + tigecycline (triple therapy for severe CRAB)
• Sulbactam + tigecycline (dual therapy)
• Colistin/polymyxin + rifampicin (600 mg daily or every 12 hours) or fosfomycin (12-24 g/day in 3-4 doses) 1, 2

Combinations to AVOID: 1, 2

• Colistin + rifampicin alone—lacks proven clinical benefit and increases hepatotoxicity
• Colistin + glycopeptides (vancomycin)—increases nephrotoxicity without added benefit
• Polymyxin-meropenem when carbapenem MIC >16 mg/L—no synergy at high-level resistance

Step 4: Newer Agents (If Available)

Sulbactam-durlobactam: 7, 8, 9

• Emerging as preferred option for CRAB with greatest mortality reduction
• Dose: 1 g/1 g every 8 hours over 3 hours (adjust for renal function)
• Use in combination with background carbapenem therapy for optimal outcomes
• Particularly effective for pulmonary infections and bacteremia

Cefiderocol: 7, 8

• Conditionally recommended against for CRAB due to suboptimal outcomes in pulmonary infections
• Consider only when no other options available

Treatment Duration

• Minimum 14 days for bacteremia, especially with severe sepsis or septic shock 2, 4
• Shorter courses (7-10 days) may be acceptable for less severe infections with good clinical response and documented catheter removal 2
• Obtain repeat blood cultures at 48-72 hours to document clearance 2

Monitoring Requirements

Renal function: 1, 2

• Monitor creatinine every 48-72 hours when using colistin (nephrotoxicity in up to 33% of patients)
• Adjust colistin maintenance dose based on creatinine clearance
• Polymyxin B does not require dose adjustment for renal function

Hepatic function: 2

• Weekly liver function tests if using rifampicin (hepatotoxicity risk)

Clinical response: 2

• Assess at 48-72 hours
• Consider repeat blood cultures to document clearance
• If worsening, escalate to combination therapy or alternative agents

Critical Pitfalls to Avoid

• Never use tigecycline as monotherapy for bacteremia—suboptimal serum concentrations lead to treatment failure 2, 7
• Never use standard-dose sulbactam (6 g/day) for severe infections—inadequate for critically ill patients 2, 5
• Never delay appropriate therapy while awaiting susceptibility results in critically ill patients with known CRAB colonization 2
• Never use carbapenems as monotherapy in areas with high CRAB prevalence (>25% resistance rates) 2
• Never retain the catheter—removal is essential for cure 3, 4

Dosing Summary for Normal Renal Function

Agent	Loading Dose	Maintenance Dose	Infusion Duration
Ampicillin-sulbactam	Not required	3 g sulbactam q8h	4 hours [1,2]
Colistin	6-9 million IU	4.5 million IU q12h	Standard [1]
Polymyxin B	2-2.5 mg/kg	1.5-3 mg/kg/day ÷2	Standard [1]
Tigecycline	100-200 mg	50-100 mg q12h	Standard [1,2]
Rifampicin	Not required	600 mg daily or q12h	Standard [1,2]